{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-241415","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2025-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.525220+00:00","generated_at":"2026-05-17T03:35:10.587048+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Taysha regains full rights to TSHA-102 for Rett syndrome after Astellas option expires","bullets":["Regained full rights to lead TSHA-102 program after 2022 Option Agreement with Astellas expired.","TSHA-102 has FDA Breakthrough Therapy designation; Part A REVEAL data showed 100% response rate on primary endpoint.","REVEAL pivotal trial dosing of first patient scheduled this quarter; FDA alignment on protocol and SAP obtained.","Unencumbered rights enable full strategic flexibility and optionality for Taysha."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-241415","json":"https://secwatch.observer/filing/0001193125-25-241415.json","markdown":"https://secwatch.observer/filing/0001193125-25-241415.md","text":"https://secwatch.observer/filing/0001193125-25-241415.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312525241415/0001193125-25-241415-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312525241415/d35488d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:35:10.587048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}